Chickenpox (Varicella-Zoster Virus - HHV-3)
For the why behind the fact
Use this page to connect what you are memorizing.
Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.
Overview
Plain-Language Overview
Chickenpox is the first infection with varicella-zoster virus (VZV). It spreads through the air and contact with infected blister fluid. It usually causes an itchy rash, often with spots and blisters at different stages, most concentrated on the trunk. Fever or tiredness may occur, but the rash can be the first sign in children. Vaccination greatly lowers the risk; breakthrough illness may have only a few spots without obvious blisters. Most healthy children recover with supportive care, while adults, pregnant people, newborns and people with weakened immunity may have more serious illness. The virus remains dormant in sensory nerves and can later reactivate as shingles.
Clinical Definition
Varicella (chickenpox) is primary infection with VZV, a DNA herpesvirus (HHV-3). After mucosal/lymphoid replication, viremia spreads infection to skin and mucosa. Typical unvaccinated disease produces itchy successive crops of macules, papules, vesicles and crusts, with different stages present together and the greatest lesion density on the trunk. Breakthrough disease after vaccination may be mainly maculopapular with little fever. VZV persists in sensory ganglia; reactivation causes herpes zoster. Transmission is airborne and by direct contact. Skin bacterial superinfection, pneumonia and neurologic complications are important risks.
Inciting Event
Inhalation of aerosolized VZV, particularly from varicella or zoster lesions, or direct contact with infected lesion fluid can initiate primary infection in a susceptible person.
Exposure to someone with chickenpox or shingles can cause chickenpox in a susceptible contact; shingles itself is reactivation, not the primary illness acquired from that contact.
VZV survives poorly outside the host; focus prevention on infectious people, airborne spread and lesion contact rather than treating fomites as a major transmission route.
Latency Period
The incubation period from exposure to symptom onset is typically 10-21 days.
VZV remains latent in sensory ganglia for years to decades before possible reactivation.
A brief fever/malaise prodrome is more typical in adolescents and adults; in children, rash is often the first sign.
Diagnostic Delay
Early rash may be mistaken for insect bites or other viral exanthems, delaying diagnosis.
Mild or atypical presentations in vaccinated individuals can lead to underrecognition.
Lack of awareness of recent exposure or vaccination status may cause diagnostic uncertainty.
Initial symptoms like fever and malaise are nonspecific, leading to delayed suspicion.
Clinical Presentation
Signs & Symptoms
Fever, malaise and headache may precede the rash by 1-2 days, especially in older patients; children may have rash first and breakthrough disease may have little fever.
Development of a pruritic, generalized vesicular rash that evolves through multiple stages simultaneously.
Lesions typically begin on the face and trunk before spreading to extremities.
Mild lymphadenopathy and sore throat may accompany the rash.
In children, symptoms are usually mild, whereas adults may experience more severe systemic symptoms.
History of Present Illness
Ask about exposure, vaccination, fever and rash timing; a prodrome is not required for diagnosis.
Rash progresses from macules to papules to vesicles and then crusts over within 4-7 days.
Lesions appear in successive crops over several days, resulting in lesions at different stages simultaneously.
The rash often begins on the scalp, face or trunk and extends to the limbs, but remains centripetal in density: trunk greater than distal extremities.
Associated symptoms may include anorexia, irritability, and mild respiratory symptoms.
Past Medical History
History of immunodeficiency or immunosuppressive therapy increases risk of severe disease.
Lack of prior varicella vaccination or previous varicella infection is relevant.
History of atopic dermatitis may predispose to more severe skin involvement.
Pregnancy status is important due to risk of complications.
Family History
Family members with recent varicella infection indicate potential exposure.
Chickenpox is an acquired viral infection without a simple inherited pattern; a family history of immune deficiency may still matter when assessing unusually severe infection.
Household clustering is common due to highly contagious nature of VZV.
Physical Exam Findings
Presence of a vesicular rash with lesions in various stages including macules, papules, vesicles, pustules, and crusts.
Lesions are typically pruritic and distributed centripetally, involving the trunk, face, and extremities.
Mucosal involvement with vesicles and ulcers in the oral cavity is common.
Fever and mild lymphadenopathy may be observed during the acute phase.
In breakthrough varicella, lesions may be sparse and mainly maculopapular, without the classic vesicular appearance.
Diagnostic Workup
Diagnostic Criteria
Suspect varicella from exposure and an itchy rash in successive crops, usually concentrated on the trunk. Classic unvaccinated disease can be recognized clinically, but PCR from skin lesions or scabs is preferred for confirmation, especially in breakthrough, atypical, severe or outbreak cases. Fever and visible vesicles are not required in vaccinated patients. IgM, DFA and Tzanck testing are less reliable; a Tzanck smear cannot distinguish HSV from VZV.
Pathophysiology
Key Mechanisms
Primary infection with varicella-zoster virus (VZV, HHV-3) causes viremia and widespread infection of the skin and mucous membranes.
VZV establishes latency in sensory ganglion neurons, including dorsal-root and cranial-nerve ganglia; later reactivation produces herpes zoster.
Cell-mediated immunity controls viral replication and limits disease severity, with impaired immunity leading to more severe disease.
Viral replication in epidermal cells causes characteristic vesicular rash and systemic symptoms.
Viral replication and the host inflammatory response produce systemic illness; immune-complex deposition is not the defining mechanism of ordinary chickenpox.
| Involvement | Details |
|---|---|
| Organs | Skin is the main organ affected, showing the classic pruritic vesicular rash. |
Lungs can be involved in severe cases causing varicella pneumonia, especially in adults and immunocompromised patients. | |
Central nervous system may be affected in rare cases causing encephalitis or cerebellar ataxia. | |
| Tissues | After initial mucosal/lymphoid replication and viremia, infection of epidermal keratinocytes produces skin vesicles; the epidermis is not the initial replication site. |
Regional lymphoid tissue participates in early viral replication as well as the immune response before widespread skin disease. | |
| Cells | T cells mediate cellular immunity critical for controlling varicella-zoster virus infection and preventing dissemination. |
Keratinocytes are infected by the virus, leading to characteristic vesicular skin lesions. | |
Dendritic cells present viral antigens to initiate adaptive immune responses. | |
| Chemical Mediators | Interferon-gamma is produced by activated T cells and enhances antiviral immunity against varicella-zoster virus. |
Cytokines such as IL-1 and TNF-alpha contribute to inflammation and fever during infection. |
Treatments
Pharmacological Treatments
Acyclovir
- Mechanism:
Viral thymidine kinase begins phosphorylation; host enzymes form active acyclovir triphosphate, which inhibits viral DNA polymerase and terminates DNA-chain elongation.
- Side effects:
Acute kidney injury from renal tubular crystal precipitation, particularly with IV therapy, dehydration or excessive dosing; adjust for renal function and maintain hydration.
Headache
Nausea
- Clinical role:
Supportive care usually suffices for healthy children with uncomplicated varicella. Oral acyclovir may be considered for higher-risk uncomplicated cases, ideally within 24 hours of rash onset; IV acyclovir is recommended for severe/disseminated disease and immunocompromised patients.
Valacyclovir
- Mechanism:
Prodrug of acyclovir with improved oral bioavailability that inhibits viral DNA polymerase.
- Side effects:
Headache
Gastrointestinal upset
Acute kidney injury and neurotoxicity, especially with renal impairment or excessive dosing; dose adjustment is important.
- Clinical role:
Oral alternative for selected patients when antiviral therapy is indicated, ideally started within 24 hours of rash onset; not routine treatment for every healthy child and not a substitute for IV acyclovir in severe disease.
Famciclovir
- Mechanism:
Prodrug converted to penciclovir that inhibits viral DNA polymerase.
- Side effects:
Headache
Nausea
Renal injury may occur with excessive dosing for kidney function; renal dose adjustment is required.
- Clinical role:
May be considered for selected adult VZV infections under clinical guidance, but U.S. labeling covers zoster/HSV rather than primary chickenpox; it is not an established routine pediatric second-line treatment.
Varicella-zoster immune globulin (VZIG)
- Mechanism:
Provides passive immunity by supplying antibodies against varicella-zoster virus.
- Side effects:
Injection site reaction
Allergic reaction
- Clinical role:
Post-exposure prophylaxis, not treatment of established chickenpox: give eligible susceptible high-risk contacts who cannot receive live vaccine VariZIG as soon as possible, within 10 days of exposure under CDC guidance.
Non-pharmacological Treatments
Maintain skin hygiene and keep nails trimmed to prevent secondary bacterial infection of vesicles.
Cool baths/compresses and topical calamine can ease itching; encourage fluids. Antipyretic and antiviral drug choices depend on age, contraindications and severity.
People can spread VZV for 1-2 days before the rash. Begin isolation as soon as chickenpox is suspected and continue until all lesions crust. If a vaccinated patient has lesions that never crust, continue isolation until 24 hours pass without new lesions.
Prevention
Pharmacological Prevention
Two doses of live attenuated varicella vaccine prevent primary varicella in eligible people without evidence of immunity; routine childhood doses are at 12-15 months and 4-6 years, with catch-up schedules for older patients.
After exposure, eligible people without evidence of immunity should receive varicella vaccine ideally within 3-5 days. Later vaccination still protects against future exposures if infection did not occur.
VariZIG is for susceptible high-risk contacts after significant exposure when live vaccine cannot be given, such as certain pregnant, immunocompromised, neonatal or premature-infant contacts. Give promptly, up to 10 days after exposure; being unvaccinated alone is not sufficient.
Non-pharmacological Prevention
When caring for a patient with suspected or confirmed varicella, use standard, airborne and contact precautions throughout the infectious period.
Hand hygiene and avoiding lesion contact help, but respiratory droplet precautions alone do not replace airborne precautions in healthcare settings.
Avoiding contact with susceptible high-risk populations such as pregnant women and immunocompromised persons.
Screening for varicella immunity in healthcare workers and susceptible contacts.
Outcome & Complications
Complications
Varicella pneumonia is a serious complication, particularly in adults and immunocompromised individuals.
Bacterial superinfection of skin lesions leading to cellulitis or abscess formation.
Encephalitis and cerebellar ataxia can occur as neurologic complications.
Reye syndrome is a rare but severe complication associated with aspirin use during infection.
Disseminated varicella can cause pneumonia, hepatitis, encephalitis or coagulopathy in high-risk hosts. Congenital varicella syndrome after early maternal infection may cause dermatomal scars, limb hypoplasia and eye/brain abnormalities.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Chickenpox (Varicella-Zoster Virus - HHV-3) versus Herpes Simplex Virus (HSV) Infection
Chickenpox (Varicella-Zoster Virus - HHV-3) | Herpes Simplex Virus (HSV) Infection |
|---|---|
Pruritic vesicular rash progressing to crusted lesions in successive crops | Painful grouped vesicles on erythematous base, often localized |
Usually one primary generalized illness followed by latency; repeat clinical varicella is uncommon. | Often recurrent localized disease, but primary infection and asymptomatic infection also occur. |
Airborne spread or direct contact with infectious varicella/zoster lesion fluid. | Mucocutaneous contact can transmit HSV during symptomatic lesions or asymptomatic shedding. |
Chickenpox (Varicella-Zoster Virus - HHV-3) versus Hand, Foot, and Mouth Disease (Coxsackievirus A16)
Chickenpox (Varicella-Zoster Virus - HHV-3) | Hand, Foot, and Mouth Disease (Coxsackievirus A16) |
|---|---|
Generalized vesicular rash including trunk and face | Vesicles primarily on hands, feet, and oral mucosa |
Common in children but can affect all ages | Common in children under 5 years |
Fever with malaise and widespread pruritic rash | Mild fever and malaise with oral ulcers |
Chickenpox (Varicella-Zoster Virus - HHV-3) versus Impetigo (Staphylococcus aureus or Streptococcus pyogenes)
Chickenpox (Varicella-Zoster Virus - HHV-3) | Impetigo (Staphylococcus aureus or Streptococcus pyogenes) |
|---|---|
Vesicular rash evolving to crusted lesions | Honey-colored crusts often follow ruptured vesicles or pustules; toxin-producing S. aureus can cause flaccid bullae. |
VZV lesion PCR is preferred when confirmation is needed; DFA and Tzanck are less reliable. | Usually diagnosed clinically; culture of exudate identifies the organism when needed and can guide treatment. |
Often supportive care in healthy children; selected higher-risk patients need oral antivirals, and severe disease needs IV therapy. | Appropriate topical or oral antibiotics treat bacterial disease; response supports management but is not a definitive diagnostic test. |
Chickenpox (Varicella-Zoster Virus - HHV-3) versus Scabies
Chickenpox (Varicella-Zoster Virus - HHV-3) | Scabies |
|---|---|
Generalized crops with centripetal lesion density, greatest on the trunk, despite extension to limbs. | Burrows and papules in interdigital spaces, wrists, and genitalia |
Pruritus often present but not characteristically nocturnal | Intense nocturnal pruritus |
PCR of a skin lesion or scab confirms VZV; a Tzanck smear cannot specifically confirm chickenpox. | Identification of mites or eggs on skin scraping |
Chickenpox (Varicella-Zoster Virus - HHV-3) versus Erythema Multiforme
Chickenpox (Varicella-Zoster Virus - HHV-3) | Erythema Multiforme |
|---|---|
Vesicular lesions progressing to crusted papules | Target lesions with central dusky area and concentric rings |
Primary infection with varicella-zoster virus | Usually infection-triggered, especially HSV; medications are a less common trigger. Distinguish EM from SJS/TEN. |
Viral illness with characteristic rash and potential for latency | Usually a self-limited immune-mediated episode, but recurrent or persistent EM can occur. |